Enzymotec Ltd. Announces Publication Acceptance of Clinical Study Results on K-REAL(TM) Usage Health Benefits
December 03 2013 - 7:00AM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients, announced
today the acceptance for future publication of its clinical study
results evaluating the health benefits of K-REAL™, krill oil,
compared with fish oil.
The article manuscript titled "Enhanced increase of omega-3
index in healthy individuals with response to 4-week n-3 fatty acid
supplementation from krill oil versus fish oil" was accepted for
publication in the peer-reviewed "Journal of Lipids in Health and
Disease." The study was conducted by the Richardson Centre for
Functional Foods and Nutraceuticals, Winnipeg, Canada.
Enzymotec's double blind, randomized, placebo-controlled
crossover study included three treatments periods. Each treatment
period lasted four weeks and was separated by washout phases of
eight weeks. The study aimed to evaluate the effect of 500 mg
K-REAL™ with three capsules taken in the morning and three at
night. Differences between krill oil, fish oil, and placebo control
interventions were analyzed.
Study results indicate that K-REAL™, krill oil, is more
effective than fish oil in reducing n-6:n-3 polyunsaturated fatty
acid ratios, and improving the level of EPA and DHA accumulated in
the red blood cells (omega-3 index). Due to structural differences,
bioavailability of krill oil, a phospholipid based oil, could be
higher than fish oil, a triglyceride-based oil, conferring
properties that render it more effective than fish oil in
increasing omega-3 index and thereby, reducing cardiovascular
disease risk.
"We are pleased with the results of the study which are
consistent with previous clinical studies on other ingredients
developed and manufactured by Enzymotec," said Dr. Ariel Katz,
President and Chief Executive Officer of Enzymotec Ltd. "We will
continue to capitalize on consumer trends towards supplementing
their diets with premium health and wellness products like our
K-REAL™, krill oil."
"We are very pleased with the results of this study. The
assumption that omega-3 fatty acids are better absorbed when they
are bound to phospholipids rather than triglycerides, was suggested
as one of the main benefits of krill oil. However, nobody was able
to show it so far. This is the first well designed study proving
that consumption of krill oil is more efficient than fish oil in
elevating the level of omega-3 fatty acids in the red blood cells,"
said Dr. Peter Jones, the principal investigator of this study.
K-REAL™ is a family of solutions extracted from sustained
Antarctic Krill. It is comprised from a mixture of natural
phospholipids conjugated to EPA and DHA, astaxanthin and TG with
EPA and DHA. K-REAL™ by Enzymotec has been proven to be
significantly more effective than fish oil in increasing omega-3
index.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-functional lipid ingredients, as well as
final products, based on sophisticated processes and
technologies.
Forward Looking Statement
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: a high proportion of the
sales of our InFat product is sold to end users by a single company
in China; we rely on our Swedish joint venture partner to
manufacture InFat, and certain matters related to the joint venture
are or, based on communications from our joint venture partner, are
the subject of disagreement; our gross profits may be adversely
affected if we are only able to obtain lower quality krill meal;
our ability to obtain krill may be affected by conservation
regulation or initiatives; we are dependent on a single facility
that houses the majority of our operations; we may not be able to
expand our production or processing capabilities or satisfy growing
demand; our product development cycle is lengthy and
uncertain, and our development or commercialization efforts for our
products may be unsuccessful; we are subject to significant and
increasing government regulations regarding the sale and marketing
of our products; we may not be able to protect our proprietary
technology or prevent its unauthorized use by third parties; we are
currently subject to litigation, and in the future may become
subject to additional litigation, regarding intellectual property
rights; and other factors discussed under the heading "Risk
Factors" in the Company's final prospectus for its initial public
offering filed with the Securities and Exchange Commission on
September 30, 2013. Forward-looking statements in this release are
made pursuant to the safe harbor provisions contained in the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are made only as of the date hereof, and
the company undertakes no obligation to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
Katie.turner@icrinc.com
-or-
John Mills
310-954-1105
John.mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024